Adherence to disease-modifying therapies in Spanish patients with relapsing multiple sclerosis: Two-rear interim results of the global adherence project

European Neurology

Volumn 65, Issue 2, 2011, Pages 59-67

  Arroyo, E ^a   Grau, C ^a   Ramo Tello, C ^b   Parra, J ^a   Sanchez Solino O ^a  

^a Medical Department   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Disease modifying therapy; Multiple sclerosis; Patient adherence; Patient education

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIAL CLASS; SPAIN; TREATMENT DURATION;

ADULT; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RETROSPECTIVE STUDIES; SPAIN;

EID: 78650863996     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323216     Document Type: Article

References (12)

1. World Health Organization Report: Adherence to Long-Term Therapies. Geneva, WHO, 2003.
2. Tremlett HL, Ogel J: Interrupted therapy: stopping and switching of the β-interferon (Pubitemid 37025380)
3. Río J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, Arévalo MJ, Nos C, Montalban X: Factors related with treatment adherence to interferon-β and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-309. (Pubitemid 40775187)
4. Taus C, Taffi R, Morelli M, Fie A, Angeleri VA, Sgolastra M: Adherence to IFN-β therapy in MS: an Italian clinical setting. Mult Scler 2001; 7(suppl 1):S65.
5. Devonshire V, Lapierre Y, Macdonell R, et al: The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2010 (in press).
6. Frohman E, Phillips T, Kokel K, Van Pelt J, O'Leary S, Gross S, Hawker K, Racke M: Disease- modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002; 8: 227-236. (Pubitemid 34810404)
7. Treadaway KD, Brannon KD, Morrison A, Remmington GM: Factors that influence adherence with disease-modifying therapy in multiple sclerosis (abstract). Neurology 2006; 66(suppl 2):A30.
8. Holland N, Wiesel P, Cavallo P, Edwards C, Halper J, Kalb R, Morgante L, Namey M, O'Leary M, Smith-Williamson L: Adherence to disease-modifying therapy in multiple sclerosis: part I. Rehabil Nurs 2001; 26: 172-176.
9. Holland N, Wiesel P, Cavallo P, Edwards C, Halper J, Kalb R, Morgante L, Namey M, O'Leary M, Smith-Williamson L: Adherence to disease-modifying therapy in multiple sclerosis: part II. Rehabil Nurs 2001; 26: 221-226.
10. Fiore AP, Fragoso YD: Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months. Arq Neuropsiquiatr 2005; 63: 738-740. (Pubitemid 41494489)
11. Duque B, Sepulcre J, Bejarano B, et al: Memory decline evolves independently of disease activity in MS. Mult Scler 2008; 14: 947-953.
12. Bruce JM, Hancock LM, Arnett P, Lynch S: Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 2010; 33: 219-227.